EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.

about

EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.

Item

http://www.wikidata.org/entity/Q47780922

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

EGFR and KRAS mutations do not ...... resected lung adenocarcinoma.

@en

EGFR and KRAS mutations do not ...... resected lung adenocarcinoma.

@nl

type

Item

label

EGFR and KRAS mutations do not ...... resected lung adenocarcinoma.

@en

EGFR and KRAS mutations do not ...... resected lung adenocarcinoma.

@nl

prefLabel

EGFR and KRAS mutations do not ...... resected lung adenocarcinoma.

@en

EGFR and KRAS mutations do not ...... resected lung adenocarcinoma.

@nl

P1476

EGFR and KRAS mutations do not ...... n resected lung adenocarcinoma

@en

P2093

Alexander Dobrovic

http://www.w3.org/2001/XMLSchema#string

Benjamin Solomon

http://www.w3.org/2001/XMLSchema#string

Gavin M Wright

http://www.w3.org/2001/XMLSchema#string

Hongdo Do

http://www.w3.org/2001/XMLSchema#string

Matthew Conron

http://www.w3.org/2001/XMLSchema#string

Melissa M Moore

http://www.w3.org/2001/XMLSchema#string

Prudence A Russell

http://www.w3.org/2001/XMLSchema#string

Sue-Anne McLachlan

http://www.w3.org/2001/XMLSchema#string

Vijaya Sundararajan

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning and expression of an IL-6 signal transducer, gp130

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P2888

s12032-017-1031-1

P304

175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-017-1031-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Timothy D Clay

P577

2017-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28879441

http://www.w3.org/2001/XMLSchema#string

P921

phosphorylation